CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 2,532 enrolled
Drug / intervention
Genotyping +1 moregenetic
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00832962
NCT00832962N/ACompleted

Effectiveness of Routine Fetal RhD Genotyping for RhD- Pregnant Women

Assistance Publique - Hôpitaux de Paris·observational·Posted Jan 30, 2009·Updated Mar 26, 2015

In Brief

An observational study evaluating Genotyping and Usual prophylaxis for Rhesus Negative Pregnant Women. Completed, enrolled 2,532 participants across 1 site.

Detailed Summary

The study is divided in two sub-studies. The first one is an economical and performance comparison between two antenatal management strategies of RhD negative pregnant women: the first one will comprise non invasive RhD fetal typing during the second trimester of pregnancy (GENIFERH 1 RhD typing group), and the second will be a conventional management, i.e. without RHD fetal typing (GENIFERH 1 control group). The two groups will consist of 13 maternity wards spread over French territory. The second study (GENIFERH 2) is an evaluation of RhD fetal typing diagnostic performance and biological feasibility in routine antenatal practice with development of knew technical support; it will be based on more than 3500 fetal genotypings performed during one year by the five laboratories participating at the two studies.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesFrance
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 30, 2009
Enrollment StartJan 1, 2009
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 17.4 years ago

Interventions

Genotypinggenetic

Whole blood sample

Usual prophylaxisother

Prophylactic anti-RhD